Annual hazard rates of recurrence for breast cancer after primary therapy.
about
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trialSignificance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patientsAn early peak of relapse after surgery for breast cancerRecent translational research: computational studies of breast cancerMolecular biology of breast cancer metastasis. The use of mathematical models to determine relapse and to predict response to chemotherapy in breast cancer.Biological markers of invasive breast cancerLoss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor αThe reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I-III) 3 years after surgeryMultimodal hazard rate for relapse in breast cancer: quality of data and calibration of computer simulation.Using clinical trial data to tailor adjuvant treatments for individual patients.Variables with time-varying effects and the Cox model: some statistical concepts illustrated with a prognostic factor study in breast cancerChaperonin CCT-mediated AIB1 folding promotes the growth of ERα-positive breast cancer cells on hard substratesRecurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life.Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study.Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IXEvaluation of microRNA-10b prognostic significance in a prospective cohort of breast cancer patients.Postmastectomy locoregional recurrence and recurrence-free survival in breast cancer patients.The value of FATS expression in predicting sensitivity to radiotherapy in breast cancerDifferences in metastatic patterns in relation to time between primary surgery and first relapse from breast cancer suggest synchronized growth of dormant micrometastasesFactor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancerIntraoperative radiotherapy for breast cancer.Adjuvant Endocrine Therapy in Early Postmenopausal Breast CancerPredictors and outcomes of surgeons' referral of older breast cancer patients to medical oncologistsTime-varying pattern of postoperative recurrence risk of early-stage (T1a-T2bN0M0) non-small cell lung cancer (NSCLC): results of a single-center study of 994 Chinese patients.Minimizing early relapse and maximizing treatment outcomes in hormone-sensitive postmenopausal breast cancer: efficacy review of AI trials.Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.Crossover effects of estrogen receptor status on breast cancer-specific hazard rates by age and race.Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.Bayesian Hierarchical Multiresolution Hazard Model for the Study of Time-Dependent Failure Patterns in Early Stage Breast Cancer.What can be learnt about disease progression in breast cancer dormancy from relapse data?The difference in prognostic factors between early recurrence and late recurrence in estrogen receptor-positive breast cancer: nodal stage differently impacts early and late recurrence.Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole--of clinical importance?Adjuvant hormonal therapy in premenopausal women with operable breast cancer: not-so-peripheral perspectivesAssessing the efficacy of targeted therapy using circulating epithelial tumor cells (CETC): the example of SERM therapy monitoring as a unique tool to individualize therapy.Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast cancerEvaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy.Mammoplasty for symmetry in breast reconstruction and histologic assessment.Markers for the identification of late breast cancer recurrence.Biologic markers determine both the risk and the timing of recurrence in breast cancer.Guidelines for Osteoprotection in Breast Cancer Patients on an Aromatase Inhibitor.
P2860
Q24597456-73FC83A1-DC38-48B0-A7A6-25AFEE03326EQ24651922-CFDBB37C-A359-4715-A9D5-9D4DC0481ADDQ24796254-0291B246-EBDB-4879-8117-6A1BD67ECBF8Q24797101-C9094DCB-8F9B-4A5D-A7D0-86EDCF32D752Q24801047-ACB2DCCE-C4F8-49B3-8970-944C82465B9CQ26781177-8E9187F0-C1E8-4FD5-BB84-2EA3D192B3E7Q28308069-ED25A6C7-4EAB-4CF4-9C6D-0D232BCB99A7Q30850738-28CBB2D1-B103-4725-825E-A2EF71D98369Q30872612-8AA49A86-F247-4CE2-A8F4-37AEF03A28FEQ31122593-759BC29D-ED47-4992-9F05-BDB26E8D38AFQ33541305-671CACAD-41F8-4757-A37D-A226AE31522EQ33553729-FDF92F2C-3D21-4CAC-BF8B-4FE025BC0693Q33703527-5C369B8A-9448-40D8-8EE4-61A80A5D8F60Q33739253-1723AA96-1087-4B03-8BA9-81D90E449A59Q33739357-545EE817-7E0B-4D76-B26C-125FCB31FD8EQ33747550-0E1EC4FB-46AA-4E56-A64D-7BB5166F522CQ33846562-B09A9583-F064-4DED-AFAB-4C52B3C64B15Q33888843-E174B399-DA48-4A92-882E-580073A4D578Q33954572-AFEC4B31-144F-45E6-A51C-1E3EDB384A27Q33965106-D8DEAB01-C851-478F-AFAE-3D9ADD065563Q33973153-2DE9392C-658F-454A-9290-3253EA54975AQ34096283-2224BAB9-2CF9-47AB-A308-199C18A0F7C9Q34099121-8C5F9F93-9037-424F-9F79-E0266992CADBQ34155998-31AA74C3-B95C-41EB-ACF2-6F4B34A0A7CEQ34233815-B83A2CBE-3960-4CE0-BD7A-F96DCF956C36Q34315684-A6340D88-1AE9-407A-8F08-F1D5D2CFE66DQ34379556-76EA5FAC-9035-4E7E-A926-C8F2C1A6E46FQ34601123-2F9E065B-E3C9-4ACE-890E-180795AB822EQ34664869-3C508346-C3B1-482D-9F18-FBE137A0AC1FQ34720547-33D22810-287A-4FBB-A27F-B306953FDCC5Q34744234-26AA1EC2-E39B-4847-BE94-6CEF3145E723Q34745884-AFF77AF5-5F6A-461D-A033-1F8B43E6C7FCQ34774649-22464228-95C0-452A-9444-0310E1A87A4CQ34779138-81217624-064B-42D4-B2D8-6DE2C3ACB9E5Q34962888-9F4756F5-FEB8-4C82-8090-FE20D29B96E3Q35000713-6465C2CC-20DB-4882-B587-51D661A19121Q35014403-EDA6E0EA-0CB6-4065-B5EA-AB15451E2B8DQ35018949-E2D64B59-F3D1-47BA-8951-360C6911B6B0Q35073921-B94108E3-1DA2-4BC9-916D-DBD986690702Q35095538-C9BE8283-6275-4100-846F-9EA492A0C8A4
P2860
Annual hazard rates of recurrence for breast cancer after primary therapy.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Annual hazard rates of recurrence for breast cancer after primary therapy.
@en
Annual hazard rates of recurrence for breast cancer after primary therapy.
@nl
type
label
Annual hazard rates of recurrence for breast cancer after primary therapy.
@en
Annual hazard rates of recurrence for breast cancer after primary therapy.
@nl
prefLabel
Annual hazard rates of recurrence for breast cancer after primary therapy.
@en
Annual hazard rates of recurrence for breast cancer after primary therapy.
@nl
P2093
P1476
Annual hazard rates of recurrence for breast cancer after primary therapy.
@en
P2093
P304
P356
10.1200/JCO.1996.14.10.2738
P407
P577
1996-10-01T00:00:00Z